selective androgen receptor modulator


Also found in: Acronyms, Wikipedia.

selective androgen receptor modulator

,

SARM

A class of medications that attach to cellular binding sites for male hormones. They are designed to maximize anabolic effects while limiting side effects. They may be used to treat conditions such as male hypogonadism or age-related bone loss.
Mentioned in ?
References in periodicals archive ?
Ostarine[TM] is an oral selective androgen receptor modulator that GTx is developing for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Abstract # 9022: Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia.
DART Therapeutics, a United States-based biotechnology company, is developing a selective androgen receptor modulator drug candidate for Duchenne muscular dystrophy, a rare paediatric disease that causes genetic mutation in boys and makes them unable to make functional dystrophin, it was reported yesterday.
GTx is also developing Ostarine[TM] (GTx-024) and other selective androgen receptor modulators, or SARMs, for cancer cachexia and other muscle wasting diseases.
Ostarine (GTx-024) is a first in class selective androgen receptor modulator, or SARM, which GTx is evaluating for the treatment of cancer cachexia (muscle loss).
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens.
Nasdaq: GTXI) today announced results of a Phase II clinical trial evaluating Ostarine[TM] (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia.
The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia"
and GTx are evaluating multiple selective androgen receptor modulator (SARM) product candidates, including Ostarine[TM] (designated by Merck as MK-2866) and MK-0773 for a variety of musculoskeletal wasting indications including sarcopenia and cancer cachexia.
Researchers tested 44 products they bought online that were marketed as nonsteroidal selective androgen receptor modulators (SARMs), which mimic the effect of testosterone and help build muscle.
Researchers tested 44 products they bought online that were marketed as non-steroidal selective androgen receptor modulators (SARMs), which mimic the effect of testosterone and help build muscle.

Full browser ?